Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2012

01-04-2012 | Breast Oncology

Local Recurrence after Breast-Conserving Surgery: Multivariable Analysis of Risk Factors and the Impact of Young Age

Authors: Randy C. Miles, MD, MPH, Rachel E. Gullerud, BA, Christine M. Lohse, MS, James W. Jakub, MD, Amy C. Degnim, MD, Judy C. Boughey, MD

Published in: Annals of Surgical Oncology | Issue 4/2012

Login to get access

Abstract

Background

Local recurrence (LR) after breast conservation surgery (BCS) varies with risk factors. This study was designed to evaluate the impact of young age on LR.

Methods

All patients (excluding those who received neoadjuvant chemotherapy) who underwent BCS from 1988–2001 at our institution were identified and evaluated for risk factors of LR.

Results

A total of 3,064 patients underwent 3,131 BCS. Mean age at surgery was 61 (range, 21–98) years: 175 (5.6%) patients were aged <40 years; 492 (15.7%) were 40–49 years; 761 (24.3%) were 50–59 years; 801 (25.6%) were 60–69 years; and 902 (28.8%) were age 70 + years. A total of 212 patients (6.8%) developed LR at a mean of 4.5 (range, 0.1–14.4) years after BCS. Mean follow-up was 8.9 (range, 0–20.2) years. The 5-year LR-free survival rate was 94.9%. The frequencies of LR by age group were: <40 years—11.4%; 40–49 years—5.7%; 50–59 years—6.2%; 60–69 years—7.6%; 70 years and older—6.2%. The 5-year LR-free survival rates for these age groups were 90.5%, 95.4%, 95.5%, 95.4%, and 94.7%, respectively (P = 0.09, log-rank test). On univariable analysis, patients aged <40 years were nearly twice as likely to experience LR (hazards ratio (HR), 1.81; P = 0.012). Multivariable analysis of patients with complete data (n = 2,122) demonstrated that age <40 years and node positivity were associated with increased risk of LR, whereas ER positivity and radiation therapy were associated with decreased risk.

Conclusions

Risk factors for LR after BCS include age <40 years, node positivity, ER negativity, and absence of adjuvant radiation therapy. Patients younger than age 40 years are at increased risk of LR after BCS.
Literature
1.
Altekruse SF, Kosary CL. SEER Cancer Statistics Review 1975-2007. Bethesda, MD, National Cancer Institute, 2010.
2.
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.PubMedCrossRef
3.
Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.PubMedCrossRef
4.
Jacobson JA, Danforth DN, Cowan KH, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med. 1995;332:907–11.PubMedCrossRef
5.
van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92:1143–50.PubMedCrossRef
6.
Vicini FA, Kestin LL, Goldstein NS, et al. Impact of young age on outcome in patients with ductal carcinoma-in situ treated with breast-conserving therapy. J Clin Oncol. 2000;18:296–306.PubMed
7.
Fowble B, Hanlon AL, Fein DA, et al. Results of conservative surgery and radiation for mammographically detected ductal carcinoma in situ (DCIS). Int J Radiat Oncol Biol Phys. 1997;38:949–57.PubMedCrossRef
8.
Ray GR, Adelson J, Hayhurst E, et al. Ductal carcinoma in situ of the breast: results of treatment by conservative surgery and definitive irradiation. Int J Radiat Oncol Biol Phys. 1994;28:105–11.PubMedCrossRef
9.
White J, Levine A, Gustafson G, et al. Outcome and prognostic factors for local recurrence in mammographically detected ductal carcinoma in situ of the breast treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1995;31:791–7.PubMedCrossRef
10.
Botteri E, Bagnardi V, Rotmensz N, et al. Analysis of local and regional recurrences in breast cancer after conservative surgery. Ann Oncol. 2010;21:723–8.PubMedCrossRef
11.
Yang HC, Thornton LM, Shapiro CL, et al. Surviving recurrence: psychological and quality-of-life recovery. Cancer. 2008;112:1178–87.PubMedCrossRef
12.
Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.PubMed
13.
Jones HA, Antonini N, Hart AA, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol. 2009;27:4939–47.PubMedCrossRef
14.
Mirza NQ, Vlastos G, Meric F, et al. Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Ann Surg Oncol. 2002;9:256–65.PubMedCrossRef
15.
Jobsen JJ, van der Palen J, Ong F, et al. The value of a positive margin for invasive carcinoma in breast-conservative treatment in relation to local recurrence is limited to young women only. Int J Radiat Oncol Biol Phys. 2003;57:724–31.PubMedCrossRef
16.
Van Zee KJ, Liberman L, Samli B, et al. Long-term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age. Cancer. 1999;86:1757–67.PubMedCrossRef
17.
Jhingran A, Kim JS, Buchholz TA, et al. Age as a predictor of outcome for women with DCIS treated with breast-conserving surgery and radiation: The University of Texas M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys. 2002;54:804–9.PubMedCrossRef
18.
Bornstein BA, Recht A, Connolly JL, et al. Results of treating ductal carcinoma in situ of the breast with conservative surgery and radiation therapy. Cancer. 1991;67:7–13.PubMedCrossRef
19.
Vicini FA, Lacerna MD, Goldstein NS, et al. Ductal carcinoma in situ detected in the mammographic era: an analysis of clinical, pathologic, and treatment-related factors affecting outcome with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 1997;39:627–35.PubMedCrossRef
20.
Elkum N, Dermime S, Ajarim D, et al. Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experience. BMC Cancer. 2007;7:222.PubMedCrossRef
21.
Turaka A, Freedman GM, Li T, et al. Young age is not associated with increased local recurrence for DCIS treated by breast-conserving surgery and radiation. J Surg Oncol. 2009;100:25–31.PubMedCrossRef
22.
Vrieling C, Collette L, Fourquet A, et al. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer. 2003:39:932–44.PubMedCrossRef
Metadata
Title
Local Recurrence after Breast-Conserving Surgery: Multivariable Analysis of Risk Factors and the Impact of Young Age
Authors
Randy C. Miles, MD, MPH
Rachel E. Gullerud, BA
Christine M. Lohse, MS
James W. Jakub, MD
Amy C. Degnim, MD
Judy C. Boughey, MD
Publication date
01-04-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 4/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-2084-6

Other articles of this Issue 4/2012

Annals of Surgical Oncology 4/2012 Go to the issue

Colorectal Cancer

Is Adjuvant Chemotherapy Really Needed After Curative Surgery for Rectal Cancer Patients Who are Node-Negative After Neoadjuvant Chemoradiotherapy?

Translational Research and Biomarkers

Changes in Myostatin Signaling in Non-Weight-Losing Cancer Patients

Original Article – Hepatobiliary Tumors

Right Trisectionectomy with Principle En Bloc Portal Vein Resection for Right-Sided Hilar Cholangiocarcinoma: No-Touch Technique

Melanomas

Preoperative Ultrasound is Not Useful for Identifying Nodal Metastasis in Melanoma Patients Undergoing Sentinel Node Biopsy: Preoperative Ultrasound in Clinically Node-Negative Melanoma

Breast Oncology

Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period

Breast Oncology

Predictors of Nipple–Areolar Complex Involvement by Breast Carcinoma: Histopathologic Analysis of 787 Consecutive Therapeutic Mastectomy Specimens